文献速递临床试验与 GCP基础与转化研究

基于干血斑技术进行白血病转录本预后与筛查验证的诊断性随机对照试验:研究方案

A diagnostic randomized controlled trial to validate novel dried blood spot (DBS) based technology for prognosis and screening of leukemia transcripts: study protocol.
PubMed 文献 · Trials · 2026-04-21

本研究为多中心、随机、双盲诊断性干预试验,在印度五个中心纳入300例新诊断急性白血病患者(200例ALL、100例AML),随机分为干血斑(DBS)检测组和常规检测组,主要评价DBS方法对比常规诊断方法的灵敏度、特异度和阳性预测值,次要结局包括一年随访的总生存、无事件生存和复发率。

要点

  • DBS技术初步研究显示100%特异度和99%灵敏度(对比标准参考方法)。
  • DBS可耐受热带温湿度24-48小时,适合偏远地区运输。
  • 主要结局为DBS对比常规方法的灵敏度、特异度和阳性预测值。

核心结论

  • 该试验旨在验证基于DBS的白血病转录本检测技术,若验证成功可改善低中收入国家白血病诊断可及性。

研究设计与样本

  • 多中心、随机、双盲诊断性干预试验,在印度五个中心开展。
  • 纳入新诊断急性白血病患者300例(200例ALL、100例AML),随机分为DBS检测组和常规检测组。

主要发现

  • 初步工作显示DBS对比标准参考方法特异度100%、灵敏度99%(PLoS One 13(1):e0191421, 2019)。
  • DBS技术可耐受热带温湿度条件24-48小时。

关键数值与推荐

  • 主要结局为DBS方法对比常规诊断方法的灵敏度、特异度和阳性预测值。
  • 次要结局包括一年随访的总生存、无事件生存和复发率。

临床怎么用

  • 若验证成功,DBS技术可用于偏远地区白血病转录本检测,支持早期诊断和风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Leukemia is the most common subtype of cancer in Indian children and ranks among the top ten cancers in the adult population according to ICMR cancer registry 2022 (National Cancer Registry Programme, Cancer incidence and mortality in India 2022, 2022). Current leukemia diagnostics rely on sophisticated molecular tests that are not available at all healthcare centers, particularly in remote and tier-two cities. Access to specialized molecular diagnostics and prognostic tests is limited to fewer than 20 centers across India, serving a population of approximately 1.3 billion people (National Cancer Registry Programme, Cancer incidence and mortality in India 2022, 2022). This restricted accessibility results in delayed diagnosis, suboptimal risk stratification, increased economic burden, and higher mortality rates compared to high-income countries. METHODS: This is a multicenter, randomized, double-blind diagnostic interventional trial designed to validate a novel dried blood spot (DBS) based technology for leukemia transcript determination. The study will be conducted across five sites in India. Newly diagnosed acute leukemia patients (n = 300; 200 ALL and 100 AML) will be randomized into two arms: interventional arm (DBS-based testing) and comparator arm (conventional testing). The primary outcome is the sensitivity, specificity, and positive predictive value of the DBS-based method compared to conventional diagnostic methods. Secondary outcomes include overall survival, event-free survival, and relapse rates over one year of follow-up. DISCUSSION: This study addresses a critical gap in leukemia diagnostic accessibility in low- and middle-income countries. The novel DBS-based technology has the potential to withstand tropical temperature and humidity conditions for 24-48 h, making it suitable for transport from remote areas. Preliminary work has shown 100% specificity and 99% sensitivity compared to standard reference methods (PLoS One 13(1):e0191421, 2019). If validated, this technology could significantly improve leukemia outcomes through earlier diagnosis, better risk stratification, and reduced abandonment rates. TRIAL REGISTRATION: Clinical Trials Registry-India (CTRI): CTRI/2024/06/069601.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Sharma S, Swain SK, Rishi B, et al. A diagnostic randomized controlled trial to validate novel dried blood spot (DBS) based technology for prognosis and screening of leukemia transcripts: study protocol. Trials. 2026. PMID: 42015297. doi:10.1186/s13063-026-09571-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。